INVESTORS

SEC Filings

Form S-1
ENUMERAL BIOMEDICAL HOLDINGS, INC. filed this Form S-1 on 03/08/2017
Document Outline
Entire Document (5499.5 KB)
Subdocument 1 - S-1 - S-1
Page 1 - ENUMERAL BIOMEDICAL HOLDINGS, INC.
Page 2 - The registrant hereby amends this registration statement on such date or dates as may be necessary t
Page 3 - ENUMERAL BIOMEDICAL HOLDINGS, INC.
Page 4 - N/A
Page 5 - OTHER PERTINENT INFORMATION
Page 6 - PROSPECTUS SUMMARY
Page 7 - Capital Needs
Page 8 - N/A
Page 9 - Risks Related to our Business and the Industry in Which We Operate
Page 10 - We have incurred significant operating losses since our inception, and anticipate that we will conti
Page 11 - We will require additional capital to support operations and business growth, and such capital might
Page 12 - We rely on relationships with third parties for product development and commercialization, and those
Page 13 - Our use of our platform technology depends on a third party license that could be terminated.
Page 14 - We might be unsuccessful in obtaining adequate patent protection for one or more of our potential pr
Page 15 - If a catastrophe strikes our research facilities, we might be unable to complete our projects and ou
Page 16 - Failure to develop or maintain a trading market could negatively affect the value of our common stoc
Page 17 - We do not anticipate paying dividends on our common stock, and investors may lose the entire amount
Page 18 - Any failure to maintain effective internal control over our financial reporting could materially adv
Page 19 - The sale of a significant number of registered shares of our common stock may cause our stock price
Page 20 - SELLING STOCKHOLDERS
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - N/A
Page 40 - N/A
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - Holders
Page 46 - N/A
Page 47 - Adjustment for Awards and Payouts
Page 48 - Change in Control
Page 49 - Dividend Policy
Page 50 - Our Strategy
Page 51 - Our Programs
Page 52 - Our Proprietary Platform Technology
Page 53 - Cell Loading
Page 54 - Antibody Discovery
Page 55 - Cellular Response Profiling
Page 56 - Merck
Page 57 - Intellectual Property
Page 58 - The Merger and Related Transactions
Page 59 - Merger Agreement
Page 60 - The PPO
Page 61 - Composition of the Board; Voting Agreement
Page 62 - N/A
Page 63 - pari passu
Page 64 - Amendment of Certain Warrants to Purchase Common Stock
Page 65 - Competition
Page 66 - Government Regulation
Page 67 - Hazardous Materials
Page 68 - Legal Proceedings
Page 69 - N/A
Page 70 - Results of Operations
Page 71 - Research and development expenses
Page 72 - Three months ended September 30, 2016 as compared to three months ended September 30, 2015
Page 73 - Net income (loss)
Page 74 - Interest income (expense).
Page 75 - Cash Flows
Page 76 - Nine months ended September 30, 2016 as compared to nine months ended September 30, 2015
Page 77 - Critical Accounting Policies, Estimates, and Judgments
Page 78 - Principles of Consolidation
Page 79 - Revenue Recognition
Page 80 - Research and Development Expenses
Page 81 - Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting
Page 82 - Presentation of Financial Statements-Going Concern (Subtopic 205-40)
Page 83 - Directors and Executive Officers
Page 84 - Wael Fayad Chairman of the Board of Directors, President and Chief Executive Officer
Page 85 - Allan P. Rothstein Director
Page 86 - Robert L. Van Nostrand
Page 87 - Board Leadership Structure
Page 88 - Communicating with the Board of Directors
Page 89 - Nominating and Governance Committee
Page 90 - Code of Ethics and Business Conduct
Page 91 - Base Salary
Page 92 - N/A
Page 93 - Outstanding Equity Awards at Fiscal Year-End
Page 94 - N/A
Page 95 - Employment Agreements
Page 96 - Kevin G. Sarney
Page 97 - Arthur H. Tinkelenberg, Ph.D.
Page 98 - Anhco Nguyen, Ph.D.
Page 99 - Potential Payments upon Termination or Change in Control
Page 100 - N/A
Page 101 - N/A
Page 102 - Tinkelenberg Separation Agreement
Page 103 - Director Compensation
Page 104 - N/A
Page 105 - Director Independence
Page 106 - N/A
Page 107 - N/A
Page 108 - N/A
Page 109 - N/A
Page 110 - Common Stock
Page 111 - Warrants
Page 112 - N/A
Page 113 - N/A
Page 114 - Enumeral Biomedical Holdings, Inc.
Page 115 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 116 - Enumeral Biomedical Holdings, Inc.
Page 117 - Enumeral Biomedical Holdings, Inc.
Page 118 - Enumeral Biomedical Holdings, Inc.
Page 119 - Enumeral Biomedical Holdings, Inc.
Page 120 - ENUMERAL BIOMEDICAL HOLDINGS, INC.
Page 121 - 2 GOING CONCERN
Page 122 - 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Page 123 - Marketable Securities
Page 124 - Accounts Receivable and Allowance for Doubtful Accounts
Page 125 - Revenue Recognition
Page 126 - Grant Revenue
Page 127 - Stock-Based Compensation
Page 128 - Earnings (Loss) Per Share
Page 129 - Presentation of Financial Statements Going Concern (Subtopic 205-40)
Page 130 - 6 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Page 131 - Equipment Lease Financing
Page 132 - Employment Agreements
Page 133 - Consulting Agreements
Page 134 - 10 EQUITY
Page 135 - 11 STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS
Page 136 - N/A
Page 137 - Restricted Stock
Page 138 - Square 1 Financing
Page 139 - 12 INCOME TAX
Page 140 - 13 CONCENTRATIONS
Page 141 - N/A
Page 142 - Enumeral Biomedical Holdings, Inc.
Page 143 - Enumeral Biomedical Holdings, Inc.
Page 144 - Enumeral Biomedical Holdings, Inc.
Page 145 - ENUMERAL BIOMEDICAL HOLDINGS, INC.
Page 146 - 2 - GOING CONCERN AND LIQUIDITY
Page 147 - 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Page 148 - Cash and Cash Equivalents
Page 149 - Accounts Receivable and Allowance for Doubtful Accounts
Page 150 - N/A
Page 151 - Grant Revenue
Page 152 - Comprehensive Income (Loss)
Page 153 - Compensation Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting
Page 154 - Recent Accounting Pronouncements
Page 155 - 4 - PROPERTY AND EQUIPMENT, NET
Page 156 - Promissory Notes
Page 157 - 8 COMMITMENTS
Page 158 - Employment Agreements
Page 159 - Consulting Agreements
Page 160 - Merger
Page 161 - 11 - STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS
Page 162 - N/A
Page 163 - Restricted Stock
Page 164 - A) PPO and PPO Agent Warrants
Page 165 - 13 - SUBSEQUENT EVENTS
Page 166 - ENUMERAL BIOMEDICAL HOLDINGS, INC.
Page 167 - PART II
Page 168 - Item 15. Recent Sales of Unregistered Securities.
Page 169 - Convertible Note Offering
Page 170 - The PPO
Page 171 - N/A
Page 172 - N/A
Page 173 - N/A
Page 174 - N/A
Page 175 - Item 17. Undertakings.
Page 176 - N/A
Page 177 - IGNATURES
Subdocument 2 - EX-5.1 - EXHIBIT 5.1
Page 1 - Exhibit 5.1
Page 2 - N/A
Subdocument 3 - EX-10.39 - EXHIBIT 10-39
Page 1 - Exhibit 10.39
Page 2 - Business Day
Page 3 - Closing Price
Page 4 - Date of Exercise
Page 5 - Buy-In
Page 6 - Partial Exercise
Page 7 - Subdivision or Combination of Stock
Page 8 - Organic Change
Page 9 - Certificate as to Adjustments
Page 10 - Permitted Transfers and Assignments
Page 11 - THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMEN
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - NOTICE OF EXERCISE
Page 17 - N/A
Subdocument 4 - EX-10.40 - EXHIBIT 10-40
Page 1 - Exhibit 10.40
Page 2 - Exercise Period
Page 3 - Date of Exercise
Page 4 - Buy-In
Page 5 - General
Page 6 - Organic Change
Page 7 - Exhibit B
Page 8 - THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMEN
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - NOTICE OF EXERCISE
Page 13 - N/A
Subdocument 5 - EX-10.41 - EXHIBIT 10-41
Page 1 - Exhibit 10.41
Page 2 - Exercise Period
Page 3 - Closing Price
Page 4 - Buy-In
Page 5 - General
Page 6 - Organic Change
Page 7 - Certificate as to Adjustments
Page 8 - provided
Page 9 - N/A
Page 10 - N/A
Page 11 - Signature Page Follows
Page 12 - N/A
Page 13 - NOTICE OF EXERCISE
Page 14 - FORM OF ASSIGNMENT
Subdocument 6 - EX-23.1 - EXHIBIT 23-1
Page 1 - Exhibit 23.1
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer